• linkedin
  • Increase Font
  • Sharebar

    Recruitment underway for atopic dermatitis serlopitant trial

    Early trial results show a significant reduction of itch with the oral NK-1 antagonist serlopitant



    • Serlopitant, an oral neurokinin 1 (NK-1) receptor antagonist under clinical investigation, may be a promising treatment for severe pruritus.
    • The treatment has been evaluated as a once-daily oral treatment in 2 trials that met their primary endpoints of reducing pruritus scores vs placebo.
    • Recruitment is underway for a randomized, double-blind, placebo-controlled study of serlopitant for treatment of pruritus in adults and adolescents with a diagnosis of atopic dermatitis.




    Dr. Ständer reports she is a member of the scientific advisory board for Menlo Therapeutics.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow